Rep. Jefferson Shreve Sells Off Shares of Repligen Co. (NASDAQ:RGEN)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Repligen Co. (NASDAQ:RGEN). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Repligen stock on April 7th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 – $100,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/17/2025.
• Purchased $50,001 – $100,000 in shares of Applied Materials (NASDAQ:AMAT) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Caterpillar (NYSE:CAT) on 4/17/2025.
• Sold $15,001 – $50,000 in shares of Lululemon Athletica (NASDAQ:LULU) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Western Digital (NASDAQ:WDC) on 4/17/2025.
• Sold $15,001 – $50,000 in shares of Zoetis (NYSE:ZTS) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Ross Stores (NASDAQ:ROST) on 4/17/2025.

Repligen Trading Down 3.6%

Repligen stock opened at $123.24 on Monday. The stock has a market cap of $6.92 billion, a P/E ratio of -241.65, a PEG ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm’s 50 day moving average price is $135.03 and its 200-day moving average price is $145.44.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD lifted its stake in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after buying an additional 743,815 shares during the period. Vanguard Group Inc. lifted its holdings in Repligen by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after buying an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC lifted its position in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock valued at $222,176,000 after purchasing an additional 122,595 shares during the period. Alliancebernstein L.P. raised its position in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock valued at $145,508,000 after acquiring an additional 191,439 shares during the period. Finally, Conestoga Capital Advisors LLC raised its stake in Repligen by 3.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company’s stock worth $124,727,000 after buying an additional 32,665 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of several recent research reports. Evercore ISI initiated coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Thursday. Canaccord Genuity Group lowered their target price on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Finally, JPMorgan Chase & Co. lowered their price target on Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.